Posttreatment samples acquired secondary genetic alterations, including EGFR T790M, HER2 amplification, MET amplification, or small cell carcinoma transformation, but almost half of the samples did not show genetic abnormalities causing EGFR-TKI resistance (Figure S1). The gene discussed is MET; the disease is small cell carcinoma.